Should you buy Eli Lilly and (LLY)?
Updated
Eli Lilly is a high-quality healthcare franchise with 56% revenue growth, a wide economic moat, and four consecutive double-digit earnings beats, but the stock has effectively reached the analyst consensus price target with only 0.9% headroom remaining — the setup favors accumulation on weakness rather than initiating at current levels.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
The business carries a wide economic moat with 35% net margins and a Rule of 40 score of 68 — an exceptional combination that distinguishes the franchise within healthcare and justifies a structural valuation premium over peers. Quality breakdown | Net margin stays above 30% and the Rule of 40 remains above 55 over the next 4 quarters, confirming that profitability and growth continue to reinforce each other. | →Stable |
| CounterFree cash flow is converting at only 36% of net income — a flagged quality concern — and the balance sheet carries a debt-to-equity ratio of 1.4; if earnings growth moderates and FCF does not recover, the current premium multiple may face downward pressure. | ||
The company has beaten consensus estimates in each of the past 4 quarters, averaging roughly 14.5% upside to expectations, with the most recent quarter delivering 16.9% above the estimate. This consistent pattern of under-promising and over-delivering supports the premium multiple even at elevated price levels. Earnings | Average EPS surprise remains above 10% over the next 4 quarters with no misses, sustaining the positive earnings revision cycle. | →Stable |
| CounterWith analyst targets already reached and only 0.9% headroom remaining to the take-profit level, continued beat delivery may already be fully discounted, leaving limited room for additional multiple expansion from current prices. | ||
Revenue has grown 56% year over year, well above the typical rate for a large-cap pharmaceutical company, supporting premium multiple sustainability if this trajectory continues to outpace consensus expectations. Growth breakdown | Revenue growth stays above 30% year over year for the next 2 reported quarters, sustaining the exceptional growth narrative. | →Stable |
| CounterThe leverage on the balance sheet (debt-to-equity at 1.4) represents a financial constraint that could limit reinvestment capacity if growth moderates; higher debt service may reduce flexibility at the moment it is most needed. | ||
The business carries a wide economic moat with 35% net margins and a Rule of 40 score of 68 — an exceptional combination that distinguishes the franchise within healthcare and justifies a structural valuation premium over peers.
→Stable- Expectation
- Net margin stays above 30% and the Rule of 40 remains above 55 over the next 4 quarters, confirming that profitability and growth continue to reinforce each other.
CounterFree cash flow is converting at only 36% of net income — a flagged quality concern — and the balance sheet carries a debt-to-equity ratio of 1.4; if earnings growth moderates and FCF does not recover, the current premium multiple may face downward pressure.
The company has beaten consensus estimates in each of the past 4 quarters, averaging roughly 14.5% upside to expectations, with the most recent quarter delivering 16.9% above the estimate. This consistent pattern of under-promising and over-delivering supports the premium multiple even at elevated price levels.
→Stable- Expectation
- Average EPS surprise remains above 10% over the next 4 quarters with no misses, sustaining the positive earnings revision cycle.
CounterWith analyst targets already reached and only 0.9% headroom remaining to the take-profit level, continued beat delivery may already be fully discounted, leaving limited room for additional multiple expansion from current prices.
Revenue has grown 56% year over year, well above the typical rate for a large-cap pharmaceutical company, supporting premium multiple sustainability if this trajectory continues to outpace consensus expectations.
→Stable- Expectation
- Revenue growth stays above 30% year over year for the next 2 reported quarters, sustaining the exceptional growth narrative.
CounterThe leverage on the balance sheet (debt-to-equity at 1.4) represents a financial constraint that could limit reinvestment capacity if growth moderates; higher debt service may reduce flexibility at the moment it is most needed.
▸ Show 1 more pillar▾ Show fewer
With the stock sitting just below its analyst consensus price target — approximately 0.9% of headroom remaining to the take-profit level — the near-term reward is thin even as the risk/reward structure remains favorable at roughly 2.9-to-1. The setup favors patience over initiating new exposure at these levels.
→Stable- Expectation
- A pullback toward the 50-day moving average entry zone restores a more attractive risk/reward profile for incremental positions.
CounterA wide-moat franchise growing at 56% year over year can sustain and extend premium valuations; if analysts raise their consensus targets on continued beat delivery, the apparent ceiling resets and the current price becomes a compelling entry in retrospect.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The company has beaten consensus estimates in each of the past 4 quarters, averaging roughly 14.5% upside to expectations, with the most recent quarter delivering 16.9% above the estimate. This consistent pattern of under-promising and over-delivering supports the premium multiple even at elevated price levels.
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P2The business carries a wide economic moat with 35% net margins and a Rule of 40 score of 68 — an exceptional combination that distinguishes the franchise within healthcare and justifies a structural valuation premium over peers.
Trip ifNet margin compresses below 28% for 2 consecutive quarters.
- P3Revenue has grown 56% year over year, well above the typical rate for a large-cap pharmaceutical company, supporting premium multiple sustainability if this trajectory continues to outpace consensus expectations.
Trip ifRevenue growth falls below 20% year over year for 2 consecutive quarters.
- P4With the stock sitting just below its analyst consensus price target — approximately 0.9% of headroom remaining to the take-profit level — the near-term reward is thin even as the risk/reward structure remains favorable at roughly 2.9-to-1. The setup favors patience over initiating new exposure at these levels.
Trip ifUpside to analyst consensus price target exceeds 15% for 2 consecutive months.
How the engine reached this verdict
TrendMatrix's engine output for Eli Lilly and Company (LLY) is STRONG_BUY_WAIT with medium conviction, score 6.5/10 at $1111.72. The C-path quality+growth combination cleared its gates — quality 8.2 and growth 10.0 — with -0.28 asymmetric R:R supporting the read.
The engine's suggested entry zone is $1070.80, currently 3.8% above entry. Target $1159.08, stop $997.06, asymmetric R:R 1.77. The WAIT designation reflects entry-discipline framing — chasing into the current zone compresses asymmetry, which is why the engine separates WAIT from NOW. The engine's sizing output: 0.5% of portfolio at this asymmetry level (high-conviction tier).
On the bull side: Strong earnings beat streak (4/4); High-quality business; Strong growth profile. On the bear side: Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.4): -0.5; Expensive valuation. Active engine warnings: V8: Target reached (-1.8% upside), V9 Gate Failed: ASYMMETRY:-0.3=NEGATIVE.
BUY_NOW requires reward-to-risk (NEGATIVE) to clear OR price pulling back to the entry zone of $1070.80 with asymmetry crossing 2.5. The verdict flips to HOLD if overall score deteriorates by ~0.7 from sentiment or technical drift.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates LLY — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (4/4)
- ▸High-quality business
- ▸Strong growth profile
Bear case
- ▸Analyst target reached - limited upside remaining
- ▸Leverage penalty (D/E 1.4): -0.5
- ▸Expensive valuation